




RealRate

PHARMACEUTICAL 2020

Y-mAbs Therapeutics Inc.
Rank 137 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2020

Y-mAbs Therapeutics Inc. Rank 137 of 362



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 356% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -94%, being 209% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	211,955
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,586
Liabilities, Non-Current	1,956
Other Assets	2,359
Other Compr. Net Income	43
Other Expenses	0
Other Liabilities	1,921
Other Net Income	1,976
Property and Equipment	2,052
Research and Development	63,492
Revenues	0
Selling, General and Administrative Expense	19,512

Output Variable	Value in 1000 USD
Assets	216,366
Liabilities	17,463
Expenses	83,004
Stockholders Equity	198,903
Net Income	-81,028
Comprehensive Net Income	-81,006
Economic Capital Ratio	-94%

